$ASMBullishMed

Is Avino Silver & Gold Mines (ASM) One Of The Most Undervalued Silver Mining Stocks To Buy Now?

Avino Silver & Gold Mines (NYSEAMERICAN:ASM) reported Q1 2026 results on May 13, citing record performance. Revenue rose to $39.4m (+109% YoY), with net income $15.9m ($0.09/diluted share) and adjusted earnings $24.3m ($0.14/share). Silver was 60% of revenue at $86.42/oz. The TSX accepted a buyback of up to 8,423,566 shares (~5%). Analysts raised targets: H.C. Wainwright to $13 and Roth Capital to $8.

7/10
6/10
Med
Bullish
post-Q1 results coverage; analyst target changes and buyback notice referenced shortly after May 13
positive

The article provides fresh operating and financial datapoints plus a ~5% repurchase authorization, which can support near-term sentiment and valuation debate.

Avino reported Q1 2026 results with revenue up 109% YoY and net income of $15.9M ($0.09/share), plus a TSX-accepted buyback notice.

Likely modest positive bias for the next few sessions as traders price in stronger fundamentals and capital return, though it remains sensitive to silver/gold price moves.

Background

The piece centers on Avino Silver & Gold Mines’ Q1 2026 performance and subsequent analyst target adjustments, positioning the stock as undervalued.

Why it matters

Traders can use the reported quarter metrics and the TSX-accepted repurchase notice as near-term catalysts, while monitoring whether the outperformance is sustainable into subsequent quarters.

Market relevance

Fresh quarterly numbers plus a buyback authorization and analyst target changes provide actionable inputs for short- to medium-term positioning in a small-cap silver miner.

Market effects

Reinforces the read-through that improving throughput/automation and balance-sheet strength can re-rate small/mid-tier silver producers.

Highlights Mexico-focused silver production in Durango as a focal point for investors tracking regional output and execution.

Silver price sensitivity remains the key macro driver, with company-specific execution acting as a partial offset.

Alternative perspectives

The “undervalued” framing may overstate mispricing; the quarter’s strength could be partly commodity-price and timing-driven rather than durable cost/volume improvements.

No detail is provided on sustaining capex, grade trends, hedging, or longer-term production guidance—key items for assessing whether the record quarter is repeatable.

Key entities

  • Avino Silver & Gold Mines Ltd.

    Reported Q1 2026 results (revenue, income, EBITDA, cash flow) and received TSX acceptance for a share repurchase notice.

  • H.C. Wainwright

    Raised its price target to $13 from $12.50 and kept a Buy rating after the Q1 results.

  • Roth Capital

    Lifted its target to $8 from $7.50 and kept a Neutral rating, citing the Q1 beat and rebound in gold/silver prices.

Related articles

$DALMedAI 8/10

Delta reaffirms ’26 profit guidance | Arkansas Democrat Gazette

Delta Air Lines reaffirmed full-year 2026 adjusted earnings guidance of $6.50 to $7.50 per share, citing strong demand for premium, corporate and international travel that offset record quarterly fuel costs. Delta reported Q2 adjusted EPS of $1.56, above $1.51 expected, with revenue up 14% and capacity up 1%. Shares fell 1.8% to $87.39. Adjusted fuel expense was $4.4B, up 77%.

$AZNHighAI 8/10

AstraZeneca Plunges After New Heart Disease Drug Fails Trial

AstraZeneca said its heart disease drug Wainua failed to beat placebo in a clinical trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to AstraZeneca and Ionis Pharmaceuticals. AstraZeneca shares fell up to 10.6% in London and 5.7% on the NYSE. Rival ATTR-CM drug makers Pfizer, BridgeBio, and Alnylam initially moved higher or lower.

$WDFCMedAI 8/10

WD-40 Q3 Earnings Call Highlights

WD-40 Company (NASDAQ:WDFC) reported Q3 gross margin of 56.6% and non-GAAP net income of $31.5 million, with non-GAAP EPS of $2.33. EMEA sales rose 17% to $66.6 million and Asia-Pacific sales rose 24% to $27.3 million. FY2026 constant-currency net sales guidance is $652 million to $667 million. The board authorized a $100 million share repurchase program.

$RXSTMedAI 8/10

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight (NASDAQ:RXST) reported Q2 sales of 11 Light Delivery Devices (LDDs) and one LDD rental, lowering sales 20% and leaving an installed base of 1,166 units. Cash, cash equivalents and short-term investments were about $209M. It revised 2026 revenue to $140M-$160M, including $110M-$120M RxSight sales and $30M-$40M Alcon collaboration revenue, and raised gross margin outlook to 73%-75%.

$WDFCHighAI 9/10

Why WD-40 Stock Popped Today

WD-40 (WDFC) shares rose after the company reported fiscal 2026 Q3 net sales up 24% to $195 million and adjusted EPS of $2.33, above the $1.56 estimate. Operating income increased 47% to $40.3 million. WD-40 raised full-year guidance to net sales of $675-$690 million and adjusted EPS of $6.05-$6.35.